BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer.

ABSTRACT:

Background

Budding uninhibited by benzimidazole 1 (BUB1) is a highly conserved serine/threonine kinase, showing prominent importance for proper function during mitosis. However, little is known about BUB1 mRNA expression in breast cancer (BRCA) and its correlation with prognosis and immune infiltration. Hence, we aimed to unveil its potential as groundbreaking biomarkers for immunotherapy efficacy and the prognosis of BRCA.

Methods

Database for Annotation, Visualization, and Integrated Discovery (DAVID) is a potent tool for identifying significant clusters of genes and pathways in the resulting dataset. In this study, gene set enrichment analysis of BUB1 was conducted using DAVID. The clinical characteristics of patients with or without altered BUB1 mRNA expres

SUBMITTER: Zhou R 

PROVIDER: S-EPMC11483447 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature